- Home
- DNTH vs IMNM Comparison
DNTH vs IMNM Comparison
Compare DNTH & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DNTH
- IMNM
- Stock Information
- Founded
- DNTH 2015
- IMNM 2006
- Country
- DNTH United States
- IMNM United States
- Employees
- DNTH N/A
- IMNM N/A
- Industry
- DNTH Biotechnology: Pharmaceutical Preparations
- IMNM Medicinal Chemicals and Botanical Products
- Sector
- DNTH Health Care
- IMNM Health Care
- Exchange
- DNTH Nasdaq
- IMNM Nasdaq
- Market Cap
- DNTH 823.1M
- IMNM 747.7M
- IPO Year
- DNTH N/A
- IMNM 2020
- Fundamental
- Price
- DNTH $20.27
- IMNM $9.42
- Analyst Decision
- DNTH Strong Buy
- IMNM Strong Buy
- Analyst Count
- DNTH 8
- IMNM 5
- Target Price
- DNTH $46.43
- IMNM $28.60
- AVG Volume (30 Days)
- DNTH 291.2K
- IMNM 756.0K
- Earning Date
- DNTH 11-07-2024
- IMNM 11-13-2024
- Dividend Yield
- DNTH N/A
- IMNM N/A
- EPS Growth
- DNTH N/A
- IMNM N/A
- EPS
- DNTH N/A
- IMNM N/A
- Revenue
- DNTH $5,366,000.00
- IMNM $10,129,000.00
- Revenue This Year
- DNTH $44.94
- IMNM N/A
- Revenue Next Year
- DNTH N/A
- IMNM N/A
- P/E Ratio
- DNTH N/A
- IMNM N/A
- Revenue Growth
- DNTH 51.41
- IMNM N/A
- 52 Week Low
- DNTH $6.58
- IMNM $6.93
- 52 Week High
- DNTH $33.77
- IMNM $30.96
- Technical
- Relative Strength Index (RSI)
- DNTH 22.81
- IMNM 29.22
- Support Level
- DNTH $22.19
- IMNM $8.97
- Resistance Level
- DNTH $28.56
- IMNM $13.52
- Average True Range (ATR)
- DNTH 2.02
- IMNM 0.85
- MACD
- DNTH -0.88
- IMNM -0.30
- Stochastic Oscillator
- DNTH 3.38
- IMNM 9.59
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.
About IMNM Immunome Inc.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which itcan efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious disease, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP) and and IM-4320.